# Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma

> **NCT00600002** · PHASE1 · COMPLETED · sponsor: **Edward Nelson** · enrollment: 30 (actual)

## Conditions studied

- Resectable Pancreatic Adenocarcinoma
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** GM-CSF

## Key facts

- **NCT ID:** NCT00600002
- **Lead sponsor:** Edward Nelson
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600002, "Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00600002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*